Preclinical and clinical development of cyclin-dependent kinase modulators [Review].
Senderowicz, A. M. and Sausville, E. A. (Reprint available from: Senderowicz AM NIH Bldg 10,Rm 6N113 Bethesda, MD 20892 USA). Journal of the National Cancer Institute. 92(5):376-387, 2000 Mar 1.

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Kunisue, H.; Kurebayashi, J.; Otsuki, T.; Tang, C. K.; Kurosumi, M.; Yamamoto, S.; Tanaka, K.; Doihara, H.; Shimizu, N., and Sonoo, H. (Reprint available from: Kurebayashi J Kawasaki Med Sch, Dept Breast & Thyroid Surg 577 Matsushima Kurashiki Okayama 7010192 Japan). British Journal of Cancer. 82(1):46-51, 2000 Jan.

A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.
Gradishar, W. J.; Soff, G.; Liu, J. G.; Cisneros, A.; French, S.; Rademaker, A.; Benson, A. B., and Bouck, N. (Reprint available from: Gradishar WJ 676 N St Clair St,Suite 850 Chicago, IL 60611 USA). Oncology. 58(4):324-333, 2000.

Progress in antiangiogenic gene therapy of cancer [Review].
Feldman, A. L. and Libutti, S. K. Cancer. 89(6):1181-1194, 2000 Sep 15.

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
Eisen, T.; Boshoff, C.; Mak, I.; Sapunar, F.; Vaughan, M. M.; Pyle, L.; Johnston, S. R. D.; Ahern, R.; Smith, I. E., and Gore, M. E. (Reprint available from: Gore ME Royal Marsden Hosp, Dept Med London SW3 6JJ England). British Journal of Cancer. 82(4):812-817, 2000 Feb.

Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin) [Review].
Burris, H. A. Seminars in Oncology. 27(2 Suppl 3):19-23, 2000 Apr.

Phase II evaluation of thalidomide in patients with metastatic breast cancer.
Baidas, S. M.; Winer, E. P.; Fleming, G. F.; Harris, L.; Pluda, J. M.; Crawford, J. G.; Yamauchi, H.; Isaacs, C.; Hanfelt, J.; Tefft, M.; Flockhart, D.; Johnson, M. D.; Hawkins, M. J.; Lippman, M. E., and Hayes, D. F. Journal of Clinical Oncology. 18(14):2710-2717, 2000 Jul.

Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy [Review]. Pegram, M. and Slamon, D Seminars in Oncology. 27(5 Suppl 9):13-19, 2000 Oct.

Current and planned clinical trials with trastuzumab (Herceptin) [Review].
Baselga, J. Seminars in Oncology. 27(5 Suppl 9):27-32, 2000 Oct.

Clinical trials of single-agent trastuzumab (Herceptin) [Review].
Seminars in Oncology. 27(5 Suppl 9):20-26, 2000 Oct.